Corporate Board Profile
Tech Score: 13/100
2 mention(s) identify HEIDI HAGEN as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| Alaunos Therapeutics, Inc. | 2020-05-18 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. Since October 2015, Ms. Hagen has served as Co-founder and Advisor for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. | Ms. Hagen has degrees in cell and molecular biology, bioengineering, and an MBA, and has experience as a biotechnology and pharmaceutical operations and technology consultant, including co-founding a company that develops cloud-based software platforms. |
| Alaunos Therapeutics, Inc. | 2021-04-07 | Ms. Hagen has held the position of a biotechnology and pharmaceutical operations and technology consultant with HH Consulting LLC since October 2012. From October 2015 until March 2020, Ms. Hagen served as Co-founder and Chief Strategic Officer for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. Ms. Hagen currently is an advisor to Vineti, Inc. | Ms. Hagen co-founded Vineti, Inc., a company that develops and sells cloud-based software platforms, indicating software-related technical skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-05-18 | Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. Since October 2015, Ms. Hagen has served as Co-founder and Advisor for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. |
| 2021-04-07 | Ms. Hagen has held the position of a biotechnology and pharmaceutical operations and technology consultant with HH Consulting LLC since October 2012. From October 2015 until March 2020, Ms. Hagen served as Co-founder and Chief Strategic Officer for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. Ms. Hagen currently is an advisor to Vineti, Inc. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-03-31 | Heidi Hagen* Director 45 2013 ... Mr. Rubino (Chair), Dr. Zerbe and Ms. Hagen were members of the Compensation Committee during the fiscal year ended December 31, 2013. Ms. Hagen was a member of the Compensation Committee beginning in the third quarter of 2013. ... DIRECTOR COMPENSATION FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2013 Heidi Hagen $10,000 $0 $15,452 $0 $25,452 |
| 2014-10-21 | Heidi Hagen Fees Earned or Paid in Cash ($) 10,000, Stock Awards ($) 0, Option Awards ($) 15,452, Other Compensation ($) 0, Total ($) 25,452. Ms. Hagen joined the Board of Directors in August of 2013. Compensation Committee Members: Alan L. Rubino, Chairman, Robert L. Zerbe, M.D., Heidi Hagen. |
| 2015-03-25 | Heidi Hagen* Director 46 2013 ... Mr. Rubino (Chair), Dr. Zerbe and Ms. Hagen were members of the Compensation Committee during the fiscal year ended December 31, 2014. ... Ms. Hagen (Chair), Dr. Zerbe and Mr. Sims were members of the Governance Committee during the fiscal year ended December 31, 2014. ... DIRECTOR COMPENSATION FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2014 Heidi Hagen $37,250 Fees Earned or Paid in Cash $8,760 Stock Awards $0 Option Awards $0 Other Compensation $46,010 Total |
| 2016-03-18 | Heidi Hagen, a Director since August 2013... Mr. Rubino (Chair), Ms. Hagen and Dr. Gilman were members of the Compensation Committee during the fiscal year ended December 31, 2015... Ms. Hagen (Chair), Dr. Zerbe and Dr. Wotton were members of the Governance Committee during the fiscal year ended December 31, 2015... DIRECTOR COMPENSATION FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2015: Heidi Hagen: Total $103,330. |
| 2017-03-20 | Heidi Hagen, a Director since August 2013...Ms. Hagen (Chair), Dr. Zerbe and Dr. Wotton were members of the Governance Committee during the fiscal year ended December 31, 2016...Mr. Rubino (Chair), Ms. Hagen and Dr. Gilman were members of the Compensation Committee during the fiscal year ended December 31, 2016...DIRECTOR COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2016...Heidi Hagen 55,000 30,228 85,228 |
| 2018-03-22 | Heidi Hagen, a Director since August 2013...Ms. Hagen (Chair), Dr. Zerbe and Dr. Wotton were members of the Governance Committee during the fiscal year ended December 31, 2017...Mr. Rubino (Chair), Ms. Hagen and Dr. Gilman were members of the Compensation Committee during the fiscal year ended December 31, 2017...DIRECTOR COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2017...Heidi Hagen 56,500 Fees Earned or Paid in Cash, 31,817 Option Awards, Total 88,317. |
| 2019-03-20 | Heidi Hagen, a director since August 2013...Ms. Hagen (Chair), Dr. Zerbe and Dr. Wotton were members of the Governance Committee...Mr. Rubino (Chair), Ms. Hagen and Dr. Gilman were members of the Compensation Committee...DIRECTOR COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2018: Heidi Hagen: $219,644 total compensation. |
| 2020-03-20 | Heidi Hagen, a director since August 2013... Mr. Rubino (Chair), Ms. Hagen and Dr. Gilman were members of the Compensation Committee during the fiscal year ended December 31, 2019... Ms. Hagen (Chair), Dr. Zerbe and Dr. Wotton were members of the Governance Committee during the fiscal year ended December 31, 2019... DIRECTOR COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2019: Heidi Hagen: $230,085. |
| 2021-03-19 | Heidi Hagen, a director since August 2013, currently serves as Interim Chief Executive Officer of Ziopharm Oncology, Inc. ... Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and M.B.A. at the University of Washington. ... Vericel Board committee(s): Compensation and Governance and Nominating (Chair) Committees ... Director compensation table: Heidi Hagen Fees Earned or Paid in Cash($) 57,000, Stock Awards($) 25,480, Option Awards($) 117,439, Total($) 199,919. |
| 2022-03-17 | Heidi Hagen has been a member of the Vericel Board of Directors since 2013. ... Vericel Board committee(s): Compensation and Governance and Nominating (Chair) Committees ... Director compensation table: Heidi Hagen total $487,970. |
| 2023-03-23 | Heidi Hagen has been a member of the Vericel Board of Directors since 2013. She has extensive experience in operations management and commercializing innovative technologies, including more than 20 years in the cell and gene therapy industries. Currently, Ms. Hagen serves as Chief Technical Officer of Sonoma Biotherapeutics, a privately-held company leading the development of adoptive TREG cell therapies for autoimmune and inflammatory diseases. The director compensation table reflects all compensation awarded to, earned by or paid to our non-employee directors for the fiscal year ended December 31, 2022. Heidi Hagen received $67,500 in cash fees, $83,174 in stock awards, and $126,874 in option awards, totaling $277,548. |
| 2024-03-21 | Heidi Hagen, 55, Independent, Former Chief Technical Officer, Sonoma Biotherapeutics, Director Since: 2013, Vericel Board committee(s): Compensation and Governance and Nominating (Chair) Committees, Director compensation total: $324,641 |
| 2025-03-20 | Heidi Hagen, 56 Independent Former Chief Technical Officer, Sonoma Biotherapeutics Director Since: 2013 Vericel Board committee(s): Compensation and Governance and Nominating (Chair) Committees Director compensation table: Total $437,398 |
Data sourced from SEC filings. Last updated: 2026-02-03